This panel of leaders in the fields of healthcare, science and technology from the Black community will select five Black organizations to use the LunaPEER system to power participant-centric research. The implementation will support discovery in disparities, quality of life, education, and/or health, and put the power and control in data sharing in individuals’ and communities’ hands – a key feature of the platform.
Donna R. Cryer, JD, is the Founder and Chief Executive Officer of the Global Liver Institute, the only patient-driven liver health nonprofit operating in the US and Europe. She has channeled her personal experience as a patient with inflammatory bowel disease and a 25-year liver transplant recipient into professional advocacy across a career in law, policy, consulting, public relations, clinical trial recruitment, and nonprofit management. Mrs. Cryer is a frequent speaker on the topic of patient-centeredness in healthcare transformation, digital health, and value.
Mrs. Cryer received an undergraduate degree from Harvard/Radcliffe Colleges and a Juris Doctorate from the Georgetown University Law Center.
Tshaka Cunningham, Ph.D. is a co-founder and Chief Scientific Officer of Trugenomix Inc., an emerging precision genomics biotechnology company that is harnessing the power of genomics to improve risk prediction and diagnosis of PTSD.
He previously served as the Scientific Program Manager for the Aging and Neurodegenerative Diseases Rehabilitation Research Program at the U.S. Department of Veterans Affairs (VA), where he also served as a subject matter expert for VA’s Genomic Medicine Implementation Program (GMIP) and convened the Million Veteran Program (MVP) Diversity Working Group to maximize the participation of minority Veterans in the project. His postdoctoral training in immunology and tumor immunotherapy occurred at the Pasteur Institute in Paris, France, and at the National Institutes of Health in Bethesda, MD. In addition to his work at Trugenomix Inc., Dr. Cunningham serves on the advisory board of LunaDNA, the first health and DNA discovery platform owned by its community of data contributors.
During her 35-year career in medicine, Dr. Freda Lewis-Hall has been on the frontlines of health care as a clinician, educator, researcher, and leader in the biopharmaceuticals and life sciences industries. Freda served as Pfizer, Inc.’s Chief Medical Officer and Executive Vice President until the end of 2018 and as Chief Patient Officer and Executive Vice President during 2019. In these roles, Freda expanded outreach to patients, reshaped the focus on patient engagement and inclusion, improved health information and education, and amplified the voice of the patient within company culture and decision-making. She was responsible for the safe, effective and appropriate use of Pfizer medicines and vaccines. Freda currently serves on the Board of Fellows of The Harvard Medical School, the Board of Advisors of the Dell Medical School, the board of the Foundation of the National Institutes of Health, and the Board of Governors for the Patient-Centered Outcomes Research Institute.
Michelle McMurry-Heath assumed the leadership of the Biotechnology Innovation Organization (BIO) as President and CEO on June 1, 2020. A medical doctor and molecular immunologist by training, Dr. McMurry-Heath becomes just the third chief executive to steward the world’s largest biotechnology advocacy group since BIO’s founding in 1993.
The common thread in McMurry-Heath’s work across academia, government and industry has been her focus on broadening access to scientific progress so more patients from diverse backgrounds can benefit from cutting-edge innovation. Driven by her own past family experiences navigating clinical trials and funding uncertainties within the rare disease community, McMurry-Heath calls “the distribution of scientific progress the social justice issue of our age.”
Anonymous because of professional affiliation ethics requirements.